Valuation: Rock Creek Pharmaceuticals Inc

Market Cap 153K 134K 125K 115K 216K 14.8M 219K 1.49M 582K 7.24M 576K 563K 25.02M P/E 2014
-0.87x
P/E 2015 -1.04x
Enterprise Value 20.01M 17.53M 16.28M 14.96M 28.18M 1.93B 28.6M 194M 75.89M 945M 75.12M 73.5M 3.26B EV / Sales 2014
-
EV / Sales 2015 -
Free-Float
100%
Yield 2014 *
-
Yield 2015 -
Change 5-day change 1-year change 3-year change Capi.($)
-16.67%+25.00% - - 17.04K
-1.05%+0.55%+49.79%+151.71% 1,037B
+2.00%+3.49%+52.22%+50.20% 615B
-1.09%+3.76%+35.37%+76.22% 448B
+2.02%+2.32%+29.85%+24.06% 326B
-1.38%+0.49%+33.01%+36.41% 293B
-1.81%-1.05%+17.07%+15.92% 264B
-1.72%-6.57%-29.14%-42.95% 216B
-0.05%+2.16%+19.75%+55.89% 198B
+0.05%-1.03%+18.31%+61.63% 162B
Average -1.81%+1.12%+25.14%+47.68% 395.27B
Weighted average by Cap. -0.28%+1.47%+34.88%+72.18%

Financials

2014 2015
Net sales - -
Net income -38.52M -33.75M -31.33M -28.79M -54.25M -3.72B -55.05M -373M -146M -1.82B -145M -141M -6.28B -6.84M -6M -5.57M -5.12M -9.64M -661M -9.78M -66.33M -25.96M -323M -25.7M -25.14M -1.12B
Net Debt -45K -39.43K -36.6K -33.64K -63.38K -4.34M -64.31K -436K -171K -2.12M -169K -165K -7.34M 19.86M 17.4M 16.15M 14.84M 27.97M 1.92B 28.38M 192M 75.31M 938M 74.54M 72.93M 3.24B
Logo Rock Creek Pharmaceuticals Inc
Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.
Employees
-